Johnson & Johnson
Close on Nov 2, 2026Market cap $652.02BP/E 31.4Yield 1.90%
Johnson & Johnson VELCADE [reported separately through FY2020Q4] by Year
VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%) (%)
Johnson & Johnson VELCADE [reported separately through FY2020Q4]: -45.7% in FY2020, down 13.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2020 figure comes from
“|| WW | 408 | 751 | (45.7) | (45.8) | 0.1”
Source: Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗
Reported in Form 8-K EX-99.2 Segment Sales Schedule.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | VELCADE (bortezomib) [reported separately through FY2020Q4] — Worldwide reported growth YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2020 | Jan 3, 2021 | -45.7% | -13.0 pts | Form 8-K (a2020q4exhibit991.htm, filed 2021-01-26) ↗ |
| FY2019 | Dec 29, 2019 | -32.7% | -32.9 pts | Form 8-K (a2019q4exhibit991.htm, filed 2020-01-22) ↗ |
| FY2018 | Dec 30, 2018 | 0.2% | +9.2 pts | Form 8-K (a2018q4exhibit9915.htm, filed 2019-01-22) ↗ |
| FY2017 | Dec 31, 2017 | -9.0% | – | Form 8-K (a8k2017q4exhibit9915.htm, filed 2018-01-23) ↗ |
Cite this data
StockData. (2026). Johnson & Johnson VELCADE [reported separately through FY2020Q4] (%), annual FY2017–FY2020 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/drug-velcade-rep-yoy
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.